SudiptoMukherjeeMDPhD, MPH

PubMed

• Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
  Elias Jabbour, Vivian G Oehler, Paul B Koller, Omer Jamy, Elza Lomaia
  JAMA Oncology. 2024-11-21
• Internal Psychometric Validation of an International Burden of Illness Survey for Idiopathic Multicentric Castleman Disease.
  Matthew Franklin, Francis Shupo, Grace Wayi-Wayi, Natasa Zibelnik, Emily Jones
  Oncology and Therapy. 2024-09-01
• Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents.
  Guillermo Garcia-Manero, Rayna K Matsuno, Ali McBride, Hina Mohammed, Danny Idryo
  Clinical Lymphoma, Myeloma & Leukemia. 2024-09-01

Journal Articles

• International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
  Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood

Abstracts/Posters

• Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Determinants of Fitness for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving I...
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and My...
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Real-World Treatment Patterns and Transfusion Burden Among US Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Population Risks of Developing Myeloid Malignancies 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of CancerClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all